Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Low-density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease 2019

Junli Fan, Hui Wang, Guangming Ye, Xiaoling Cao, Xianqun Xu, Wenbin Tan, Yongxi Zhang

PII: S0026-0495(20)30107-4
DOI: https://doi.org/10.1016/j.metabol.2020.154243
Reference: YMETA 154243
To appear in: Metabolism
Received date: 26 March 2020
Accepted date: 17 April 2020

Please cite this article as: J. Fan, H. Wang, G. Ye, et al., Low-density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease 2019, Metabolism (2020), https://doi.org/10.1016/j.metabol.2020.154243

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Published by Elsevier.
Low-density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease 2019

Junli Fan¹, Hui Wang², Guangming Ye¹, Xiaoling Cao³, Xianqun Xu¹, Wenbin Tan³,⁴,†, Yongxi Zhang⁵,†

¹Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China
²Department of Laboratory Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
³Department of Cell Biology and Anatomy, School of Medicine, University of South Carolina, Columbia, South Carolina, USA
⁴Department of Biomedical Engineering, College of Engineering and Computing, University of South Carolina, Columbia, South Carolina, USA
⁵Department of infectious diseases, Zhongnan Hospital of Wuhan University, Wuhan, China

* contributed equally
† contributed equally

Corresponding authors:
Wenbin Tan, PhD, Department of Cell Biology and Anatomy, School of Medicine, and Department of Biomedical Engineering, College of Engineering and Computing, University of South Carolina, Columbia, South Carolina, 29209, USA wenbin.tan@uscmed.sc.edu

or

Yongxi Zhang, MD, Department of Infectious Diseases, Zhongnan Hospital of Wuhan University, Wuhan 430022, China znact1936@126.com

Abstract: 197 words

Word count: 1353 (text and abbreviations); References: 15; Figures: 1; Tables: 1; Supplementary table 3
Conflict of interest: The authors do not have any professional and financial affiliations that may be perceived to have biased the presentation.

Prior publication: None of the material in this manuscript has been published or is under consideration for publication elsewhere, including the Internet.

Funding: no

Abbreviation:

ALP, alkaline phosphatase

ALT, alanine aminotransferase

AST, aspartate aminotransferase

COVID-19, coronavirus disease 2019

CRP, C-reactive protein

hsCRP, high-sensitivity C-reactive protein

GGT, gamma-glutamyl transferase

HDL, high-density lipoprotein

SARS-CoV-2, severe acute respiratory syndrome coronavirus 2

TC, total cholesterol
Abstract
Background: The pandemic of coronavirus disease 2019 (COVID-19) has become a global threat to public health. The lipid pathophysiology in COVID-19 is unknown.

Methods: In this retrospective longitudinal study, we monitored the serum lipids in 17 surviving and 4 non-surviving COVID-19 cases prior to their viral infections and during the entire disease courses.

Results: In surviving cases, the low-density lipoprotein (LDL) levels decreased significantly on admission as compared with the levels before infection; the LDL levels remained constantly low during the disease progression and resumed to the original levels when patients recovered (pre-infection: 3.5 (3.0-4.4); on admission: 2.8 (2.3-3.1), p<0.01; progression: 2.5 (2.3-3.0); discharge: 3.6 (2.7-4.1); median (IQR), in mmol/L). In non-surviving patients, LDL levels showed an irreversible and continuous decrease until death (1.1 (0.9-1.2), p=0.02 versus the levels on admission). The ratio changes of LDL levels inversely correlated with ratio changes of high-sensitivity C-reactive protein levels. Logistic regression analysis showed increasing odds of lowered LDL levels associated with disease progression (odds ratio: 4.48, 95% IC: 1.55-12.92, p=0.006) and in-hospital death (odds ratio: 21.72, 95% IC: 1.40-337.54, p=0.028).

Conclusions: LDL levels inversely correlated to disease severities, which could be a predictor for disease progress and poor prognosis.

Key words: COVID-19, LDL, lipid, odds ratio
Introduction

The pandemic of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global threat to public health [1]. SARS-CoV-2 is a single-strand RNA virus with 96.3% sequence identity the bat coronavirus RaTG13 [2-4]. The spike protein of SARS-CoV-2 is responsible for entry of the host cells via binding to surface angiotensin converting enzyme 2 [2, 5]. The estimated mortality rate for COVID-19 is about 2.3%, with a range of 6 to 41 days from the onset of symptoms to death [6, 7]. The prominent pathological changes in lungs include edema, proteinaceous exudate, and multinucleated pneumocytes [8, 9]. We here first report the lipid pathophysiology in COVID-19.

Methods

We performed a retrospective longitudinal analysis of COVID-19 patients (n=21) who were admitted between January 18 and February 8, 2020, into the department of infectious diseases at Zhongnan Hospital of Wuhan University in Wuhan, China. The study was approved by the Institutional Review Board at the hospital (No. 2020011). The patients who had a routine laboratory test including lipids in our hospital between January 9 and 17, 2020 prior to their SARS-CoV2 infection and tested positive for SARS-CoV-2 during the COVID-19 epidemic were included in this study. All patients were admitted to our hospital between January 18 and February 8, 2020, and were either discharged or died by March 15, 2020. Healthy subjects (n=31) and patients with chronic obstructive pulmonary disease (COPD, n=21) who had lipid tests in our hospital between September, 2019 to October, 2019 were included as normal and non-COVID-19 controls. Electronic medical records including demographic, clinical treatment, and laboratory data, were extracted. Detailed methods were described in the supplementary
materials. Data were presented as median (interquartile range, IQR) and a Mann-Whitney U test was used to compare differences between groups.

**Results**

The average age of the patients was 62.5±12.6 years; 52% were male and 48% were female. 62% had morbidities such as diabetes, hypertension, cardiovascular disorders, hyperlipidemia, or kidney diseases. The onset symptoms of the patients were: fever (86%), cough (95%), fatigue (71%), shortness of breath (43%) and diarrhea (10%) (Table 1a). The severities of the admitted patients were 62% of mild, 19% of severe, and 19% of critical, a classification according to Chinese Center for Disease Control (CDC) guidelines [1]. Patients received standard treatments based on the guidelines of Chinese CDC, including antiviral remedies (arbidol, lopinavir and ribonavir, interferon α inhalation), anti-inflammatory treatments (corticosteroid), and immune-modulator (thymalfasin, immunoglobulin) (Table 1a). Severe and critical cases were given high-flow oxygen, non-invasive or invasive ventilation, depending on their morbidities. Seventeen patients recovered and were discharged, while four patients did not survive.

In the stage of disease progression, there were significantly higher levels of C-reactive protein (CRP) (78 (28-134) versus 15 (7-36), in mg/L, \( p=0.042 \)) and interleukin-6 (IL-6) (195 (127-280) versus 12 (4-18), in pg/ml, \( p<0.001 \)), but lower levels of CD8\(^+\) subpopulation T cells (33 (23-135) versus 273 (122-377), cells/µl, \( p=0.016 \)) in non-surviving patients as compared with the patients survived (Table 1b). Furthermore, in surviving patients, increases in levels of high-sensitivity CRP (hsCRP) were significantly associated with the disease severity (pre-infection: 1.2 (0.7-5.9); on admission: 11 (5.9-26), \( p<0.02 \); progression: 9.8 (5.3-45); discharge: 2.2 (1.2-7.0), in mg/L) (Supplementary Table S1). The number of lymphocytes (LY) decreased significantly at the time of admission as compared with before infection; it did not show a full recovery at the time of discharge (pre-infection: 1.6 (1.4-2.2); on admission: 1.0 (0.8-1.5),
p<0.02; progression: 0.9 (0.5-1.4); discharge: 1.2 (0.8-1.9), in g/L) (Supplementary Table S1). In patients did not survive, there was a continuous increase in hsCRP level or lymphopenia until death (Supplementary Table S1).

We next analyzed the serum lipid levels (in mmol/L) of the patients before they were infected by SARS-CoV-2 and during their entire courses of the disease. The average timeline of disease course was shown in Figure 1. The low-density lipoprotein (LDL) levels in all patients showed significant decreases at the time on admission as compared to the levels prior to infection (pre-infection: 3.5 (3.0-4.4); admission: 2.8 (2.3-3.1), p<0.01); the LDL levels remained relatively low during the treatment (2.5 (2.3-3.0)) and returned to the levels prior to infection in patients that survived by the time of discharge (3.6 (2.7-4.1)) (Fig. 1, Supplementary Table S1). The high-density lipoprotein (HDL) levels also showed significant decreases at the time on admission as compared to levels prior to infection (pre-infection: 1.4 (1.0-1.8); admission: 1.1 (0.8-1.4), p=0.03). Unlike LDL, HDL levels remained relatively low during the treatment stage and after recovery (progression: 1.2 (1.0-1.4); discharge: 1.0 (1.0-1.4)) (Fig. 1, Supplementary Table S1). Total cholesterol (TC) levels showed a pattern similar to LDL during the disease course (pre-infection: 5.2 (4.6-6.5); admission: 3.5 (3.3-4.1), p<0.01; progression: 4.5 (4.0-4.8); discharge: 5.2 (4.4-6.1); Fig. 1, Supplementary Table S1).

The LDL, HDL and TC levels in the patients that did not survive (n=4) decreased continuously until death (Fig. 1, Supplementary Table S1). Particularly, LDL levels showed an irreversible decrease by the most percentage (~60%) until death (1.1 (0.9-1.2), p=0.02 versus the levels on admission) (Figure 1, Supplementary Table S1). Supplementary table S2 showed a timeline of disease course for a non-surviving patient, from hospital admission to death, with continuous and irreversible decreases in LDL, HDL, and TC levels. LDL, HDL and TC levels in normal subjects and non-COVID-19 patients (COPD) control groups did not show significant difference as compared with the levels in COVID-19 patients before their viral infections (Supplementary
Table S3). Logistic regression analysis showed increasing odds of lowered LDL levels associated with disease progression (Chi-Square=7.49; \( p=0.006 \); odds ratio: 4.48, 95% IC: 1.55-12.92, \( p=0.006 \)) and in-hospital mortality (Chi-Square=10.87; \( p=0.001 \); odds ratio: 21.72, 95% IC: 1.40-337.54, \( p=0.028 \)). The ratio changes of LDL, HDL and TC inversely correlated with the ratio changes of hsCRP during the disease course (Fig.1).

Discussion

In this study, we report the dyslipidemia in COVID-19 patients and demonstrate that the degrees of decreased LDL levels have high odds associated with severity and mortality of the disease. LDL, together with other risk factors [10] such as older age, high Sequential Organ Failure Assessment, and d-dimer, may aid physicians in identifying patients with poor prognosis at an early phase.

There are several possible explanations for aberrant lipid levels in COVID-19 patients. First, it may result from a liver injury. Although liver functions only exhibit mild abnormalities in protein synthesis (Supplementary Table 1), whether lipid biogenesis has been impaired is yet to be determined. Second, viral infection induced pro-inflammatory cytokines modulate lipid metabolism including oxidation of LDL by reactive oxygen species singling to facilitate LDL clearance [11-13]. A measurement of oxidized LDL in patient’s serum will aid in determining this mechanism. Third, COVID-19 patients may have an increased vascular permeability caused by viral-induced inflammation. Exudates have been found evidently in the early phase of COVID-19 lung pathology [8]. Exudative fluids, containing high levels of protein and cholesterol, are caused by inflammation-related vascular permeability [14, 15], which may be one possible mechanism underlying our data. The major limitations of this study include a small size of patients and lack of information of specific lipoproteins and oxidized LDLs. Another limitation is
lack of a data set with lipids monitoring on a hospitalized non-COVID-19 disease group to further address the specificity between LDL levels and COVID-19 severity. We also posit that the dyslipidemia plays an important role in pathological development of COVID-19, which mechanism needs an urgent investigation. In conclusion, our results demonstrate that LDL decrease is associated with pathological course of COVID-19, which can serve a factor to access the disease progression and mortality.

**Author Contributions:** Drs Tan and Zhang had all full access all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Fan, Wang, Tan, Zhang.

Acquisition, analysis, or interpretation of data: Fan, Wang, Ye, Cao, Xu.

Drafting the manuscript: Tan

Statistical analysis: Cao, Tan

Supervision: Tan, Zhang
References

[1] Xu X, Chen P, Wang J, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci 2020;63:457-460.10.1007/s11427-020-1637-5.

[2] Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 2020;395:565-574.10.1016/S0140-6736(20)30251-8.

[3] The species severe acute respiratory syndrome-related coronavirus: Classifying 2019-ncov and naming it sars-cov-2. Nat Microbiol 2020.10.1038/s41564-020-0695-z.

[4] Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020.10.1038/s41586-020-2012-7.

[5] Wan Y, Shang J, Graham R, et al. Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS. J Virol 2020.10.1128/JVI.00127-20.

[6] Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020.10.1001/jama.2020.2648; 2762130.

[7] Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-ncov) in Wuhan, China. J Med Virol 2020;92:441-447.10.1002/jmv.25689.

[8] Tian S, Hu W, Niu L, et al. Pulmonary pathology of early phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol 2020.10.1016/j.jto.2020.02.010.

[9] Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020.10.1016/S2213-2600(20)30076-X.

[10] Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020.10.1016/S0140-6736(20)30566-3.

[11] Funderburg NT, Mehta NN. Lipid abnormalities and inflammation in HIV infection. Curr HIV/AIDS Rep 2016;13:218-225.10.1007/s11904-016-0321-0.

[12] Tsoukas MA, Farr OM, Mantzoros CS. Leptin in congenital and HIV-associated lipodystrophy. Metabolism 2015;64:47-59.10.1016/j.metabol.2014.07.017.

[13] Vu CN, Ruiz-Esponda R, Yang E, et al. Altered relationship of plasma triglycerides to HDL cholesterol in patients with HIV/HaART-associated dyslipidemia: Further evidence for a unique form of metabolic syndrome in HIV patients. Metabolism 2013;62:1014-1020.10.1016/j.metabol.2013.01.020.

[14] Light RW, Macgregor MI, Luchsinger PC, et al. Pleural effusions: The diagnostic separation of transudates and exudates. Ann Intern Med 1972;77:507-513.10.7326/0003-4819-77-4-507.

[15] Heffner JE, Sahn SA, Brown LK. Multilevel likelihood ratios for identifying exudative pleural effusions(*). Chest 2002;121:1916-1920.10.1378/chest.121.6.1916.
Figure 1 Ratio changes for LDL (A), HDL (B) and TC (C) in COVID-19 Patients during the course of disease. For each data point, the ratio is normalized to the levels of LDL, HDL and TC prior to infection for the same patient. The days listed are the duration (median (IQR)) for each period during the disease course. The date on admission is set as “day 0”. Data is presented as “mean ± 95% confidence interval”. # indicates $p<0.05$ as compared to the levels of pre-infection stage, and * indicates $p<0.05$ as compared to the levels on admission, by a Mann-Whitney U test. The sample actual values at each stage are listed in Supplementary Table S1. The ratios of hsCRP at each time point are normalized to the levels prior to infection in the same patients. Pearson correlation coefficient analysis show the ratios of hsCRP significantly inversely correlated with the ratios of LDL (D), HDL (E) and TC (F) during the disease course; n=33 data pairs for each analysis.
|                                | No. (%)                      |
|--------------------------------|-------------------------------|
|                                | Total (n=21) | Survival (n=17) | Non-survival (n=4) |
| Age, mean (s.d.)               | 62.5 (12.6) | 61.5 (9.5)       | 79.7 (14.3)*       |
| Male                           | 11 (52.3)   | 9 (53.9)         | 2 (50.0)           |
| Comorbidities                  |                |                  |                   |
| Type 2 diabetes                | 3 (14.3)     | 3 (17.6)         | 0 (0)              |
| Hypertension                   | 10 (47.6)    | 8 (35.3)         | 2 (50.0)           |
| Cardiovascular disease         | 5 (23.8)     | 3 (17.6)         | 2 (50.0)           |
| Kidney diseases                | 1 (4.8)      | 1 (5.8)          | 0 (0)              |
| Onset symptoms                 |                |                  |                   |
| Fever                          | 18 (85.7)    | 14 (82.3)        | 4 (100)            |
| Cough                          | 20 (95.2)    | 16 (94.1)        | 4 (100)            |
| Fatigue                        | 15 (71.4)    | 11 (64.7)        | 4 (100)            |
| Shortness of breath            | 9 (42.8)     | 5 (29.4)         | 4 (100)            |
| Diarrhea                       | 2 (9.5)      | 2 (11.7)         | 0 (0)              |
| Treatment                      |                |                  |                   |
| Arbidol                        | 15 (71.4)    | 12 (70.6)        | 3 (75.0)           |
| Lopinavir/ritonavir            | 7 (33.3)     | 4 (23.5)         | 3 (75.0)           |
| Interferon inhalation          | 7 (33.3)     | 4 (23.5)         | 3 (75.0)           |
| Corticosteroid                 | 3 (14.3)     | 3 (17.6)         | 0 (0)              |
| Thymalfasin                    | 6 (28.6)     | 6 (35.3)         | 0 (0)              |
| Oxygen                         | 8 (38.1)     | 4 (23.5)         | 4 (100)            |
| Mechanical ventilation         | 4 (19.0)     | 0 (0)            | 4 (100)            |

*, p<0.05, as compared to the patient group that survived.
Table 1b Laboratory tests for COVID-19 patients during the stage of disease progression

| Laboratory tests       | Reference value | Total (n=21) | Survival (n=17) | Non-survival(n=4) | p     |
|------------------------|-----------------|--------------|-----------------|-------------------|-------|
| IL-6 (pg/ml)           | 0.1-2.9         | 15 (8-79, 19)| 12 (4-18, 15)   | 195 (127-280, 4)  | <0.001|
| CRP (mg/L)             | <4              | 20 (7-45, 21)| 15 (7-36, 17)   | 78 (28-134, 4)    | 0.042 |
| CD3⁺ (cells/µl)        | 805 to 4,459    | 562 (203-939, 19)| 680 (303-945, 15)| 232 (129-340, 4) | 0.062 |
| CD4⁺ (cells/µl)        | 345 to 2,350    | 297 (135-557, 19)| 416 (172-557, 15)| 168 (108-250, 4) | 0.121 |
| CD8⁺ (cells/µl)        | 345 to 2,350    | 166 (50-336, 19)| 273 (122-377, 15)| 33 (23-135, 4)   | 0.016 |
| CD4⁺/CD8⁺ ratio        | 0.96-2.05       | 1.7 (1.2-3.1, 19)| 1.6 (1.3-2.4, 15)| 5.0 (2.0-6.2, 4) | 0.079 |
| CD19⁺ (cells/µl)       | 240 to 1,317    | 104 (49-174, 19)| 104 (49-236, 15)| 84 (34-134, 4)   | 0.650 |
| CD16⁺/CD56⁺ (cells/µl) | 210 to 1,514    | 164 (49-252, 19)| 168 (106-252, 15)| 33 (10-223, 4)   | 0.124 |

*P value is compared the group that survived with the group that did not survive by a Mann-Whitney U test. Data is presented as median (IQR, n).*
